Avastin fails to meet primary endpoint in prostate cancer trial

Friday 12 March 2010

A Phase 3 trial of Avastin (bevacizumab) in combination with docetaxel and prednisone in men with late-stage prostate cancer has failed to meet its primary endpoint of extending overall survival, the Roche Group announced.

 

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland